Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
127.60    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.80 (0.627%)
Market Cap: £310.60m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

Holding(s) in Company

6 Jul 2020 07:01

RNS Number : 0567S
PureTech Health PLC
06 July 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Puretech Health Plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (Please specify); As of 1 July 2020, following Jupiter's acquisition of Merian, the Chain of Control for Jupiter Fund Management plc, which includes Jupiter Asset Management, has changed and any disclosures going forward will be notified by Jupiter Fund Management Plc (JFM). As such this disclosure indicates that JAM no longer has responsibility for filing TR1 notifications and this responsibility has been transferred to JFM as the parent entity.

 

X

3. Details of person subject to the notification obligationiv

Name

Jupiter Asset Management Limited

City and country of registered office (if applicable)

4. Full name of shareholder(s) (if different from 3.)v

Name

Northern Trust Nominees Limited

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

1st July 2020

6. Date on which issuer notified (DD/MM/YYYY):

3rd July 2020

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

Below 5%

N/A

Below 5%

285,512,461

Position of previous notification (if

applicable)

5.04%

N/A

5.04%

237,429,696

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary Shares

 

 

GB00BY2Z0H74

N/A

Below 5%

N/A

Below 5%

SUBTOTAL 8. A

Below 5%

Below 5%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

 

N/A

 

N/A

 

N/A

 

N/A

 

N/A

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

 

N/A

 

N/A

 

N/A

 

N/A

 

N/A

 

N/A

SUBTOTAL 8.B.2

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Jupiter Fund Management Plc

Jupiter Fund Management Group Limited

Jupiter Asset Management Group Limited

Knightsbridge Asset Management Limited

Jupiter Investment Management Group Limited

Jupiter Asset Management Limited

Below 5%

N/A

Below 5%

10. In case of proxy voting, please identify:

Name of the proxy holder

N/A

The number and % of voting rights held

N/A

The date until which the voting rights will be held

N/A

11. Additional informationxvi

 

Contact :Jon Watson

 

Telephone Number : 0203 817 1672

 

Place of completion

London, UK

Date of completion

 

3rd July 2020

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLRAMLTMTJMBLM
Date   Source Headline
13th May 20197:00 amRNSVedanta Grows Series C Financing to $45.5 Million
7th May 20197:00 amRNSVedanta Prevails in Important EU Patent Opposition
26th Apr 20197:15 amRNSPRTC's Karuna Files IPO Registration Statement
25th Apr 20197:00 amRNSGelesis Gets $10.6M Grant to Support Manufacturing
24th Apr 20197:00 amRNSFinal Results
17th Apr 20197:00 amRNSBoehringer Ingelheim & PRTC Immuno-oncology Collab
15th Apr 20197:00 amRNSGelesis Receives FDA Clearance for First Product
11th Apr 20191:00 pmRNSAkili Makes CFO & General Counsel Appointments
11th Apr 20197:05 amRNSGelesis Presents Data on Effects of High-Fat Diet
11th Apr 20197:00 amRNSSonde Completes $16M Series A Financing Round
2nd Apr 20197:00 amRNSPRTC Presents Immuno-Oncology Programmes at AACR
1st Apr 201912:05 pmRNSKaruna expands Series B financing to $80 million
25th Mar 20196:00 pmRNSGelesis Preclinical Data on Restoring Gut Barrier
25th Mar 20196:00 pmRNSGelesis New Clinical Data on Impact of Gelesis100
21st Mar 20197:00 amRNSGelesis to Present at Endocrine Society Annual Mtg
18th Mar 20197:00 amRNSKaruna Announces $68 Million Series B Financing
15th Mar 20197:00 amRNSNotice of Results
7th Mar 20197:00 amRNSAkili & Shionogi Deal in Taiwan/Japan $20M upfront
5th Mar 20197:00 amRNSKaruna Appoints Chief Financial Officer
22nd Feb 20194:41 pmRNSSecond Price Monitoring Extn
22nd Feb 20194:36 pmRNSPrice Monitoring Extension
21st Feb 20197:00 amRNSPRTC to Present at Two US Investor Conferences
15th Feb 20194:41 pmRNSSecond Price Monitoring Extn
15th Feb 20194:35 pmRNSPrice Monitoring Extension
14th Feb 20197:00 amRNSVor Raises $42M to Advance Leukaemia Treatment
28th Jan 20197:00 amRNSAlivio Partners to Advance Non-opioid Pain Therapy
23rd Jan 20196:08 pmRNSVedanta Immuno-oncology Candidate Published
2nd Jan 20197:00 amRNSTotal Voting Rights
28th Dec 201812:07 pmRNSSecond Price Monitoring Extn
28th Dec 201812:02 pmRNSPrice Monitoring Extension
24th Dec 20187:00 amRNSVedanta Biosciences Raise $27M Series C Financing
17th Dec 20187:00 amRNSVedanta Initiates Phase 2 Study for Lead Candidate
10th Dec 20187:00 amRNSVedanta & BMS Immuno-Oncology Collaboration
28th Nov 20187:00 amRNSVor Granted First-in-class Immuno-oncology Patent
27th Nov 20187:00 amRNSJanssen/Vedanta Phase 1 in IBD & $12M Milestone
26th Nov 20184:40 pmRNSSecond Price Monitoring Extn
26th Nov 20184:35 pmRNSPrice Monitoring Extension
22nd Nov 201812:07 pmRNSSecond Price Monitoring Extn
22nd Nov 201812:02 pmRNSPrice Monitoring Extension
16th Nov 201812:07 pmRNSSecond Price Monitoring Extn
16th Nov 201812:02 pmRNSPrice Monitoring Extension
14th Nov 201812:07 pmRNSSecond Price Monitoring Extn
14th Nov 201812:02 pmRNSPrice Monitoring Extension
13th Nov 201811:05 amRNSFull Gelesis Data Published in the Journal Obesity
7th Nov 20187:00 amRNSPRTC to Present at Jefferies 2018 in London
6th Nov 20181:00 pmRNSVedanta Presents Data on Immuno-Oncology Candidate
5th Nov 20187:00 amRNSGelesis to Present Full Data for Lead Candidate
31st Oct 201812:07 pmRNSSecond Price Monitoring Extn
31st Oct 201812:02 pmRNSPrice Monitoring Extension
17th Oct 20187:00 amRNSKaruna Adds Sage Therapeutics CEO to Board

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.